99mTc(V)-DMSA scintigraphy in monitoring the response of bone disease to vitamin D3 therapy in renal osteodystrophy

Basit Öğe Kaydı
dc.contributor.authorSarikaya, A
dc.contributor.authorSen, S
dc.contributor.authorHacimahmutoglu, S
dc.contributor.authorPekindil, G
dc.date.accessioned2024-06-12T11:13:36Z
dc.date.available2024-06-12T11:13:36Z
dc.date.issued2002
dc.departmentTrakya Üniversitesien_US
dc.description.abstractRenal osteodystrophy (ROD) is a common and serious complication for uremic patients and patients are treated with 1,25-dihydroxy vitamin D-3. The bone scanning agent Tc-99m-phosphate has also been used to evaluate in ROD but it is not clear that bone scintigraphy has a role in the follow-up of treatment. In this study Tc-99m(V)-DMSA scintigraphy was performed in eleven patients [age 40.7 +/- 17.3 (mean +/- SD) yr] with ROD before and after vitamin D-3 therapy. Images were obtained after hemodialysis performed following tracer injection to maintain normal blood levels of the radiopharmaceutical and to reduce soft tissue activity. Lumbar vertebra-to-soft tissue uptake ratios (LUR) were quantified with the planar Tc-99m(V)-DMSA images. Alkaline phosphatase and parathyroid hormone levels after treatment had significantly decreased compared with pre-therapy. In all patients there was visually decreased uptake in bone structures after treatment. After treatment the mean LUR ratio was significantly lower than those of before treatment (3.59 +/- 2.63 vs. 1.65 +/- 0.62; p = 0.01). LUR values were correlated with pre-therapy alkaline phosphatase and parathyroid hormone. These findings indicate that Tc-99m(V)-DMSA scintigraphy is sensitive in evaluating the response of ROD to vitamin D-3 therapy.en_US
dc.identifier.endpage23en_US
dc.identifier.issn0914-7187
dc.identifier.issn1864-6433
dc.identifier.issue1en_US
dc.identifier.pmid11922204en_US
dc.identifier.scopus2-s2.0-0036010245en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage19en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23593
dc.identifier.volume16en_US
dc.identifier.wosWOS:000174254300003en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofAnnals Of Nuclear Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRenal Osteodystrophyen_US
dc.subjectScintigraphyen_US
dc.subjectTc-99m(V)-DMSAen_US
dc.subjectTc-99m Dimercaptosuccinic Aciden_US
dc.subjectWhole-Body Retentionen_US
dc.subjectConcise Communicationen_US
dc.subjectHyperparathyroidismen_US
dc.subjectMetabolismen_US
dc.subjectFailureen_US
dc.subjectSpecten_US
dc.subjectScanen_US
dc.title99mTc(V)-DMSA scintigraphy in monitoring the response of bone disease to vitamin D3 therapy in renal osteodystrophyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu